Uniplex

Quick links to important sections

Uniplex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uniplex

Quick Facts

Feature Details
Classification Specific Combined Vitamin Preparation
Primary Role Nutritional Supplementation
Active Components Thiamine (B1), Riboflavin (B2), Nicotinamide (B3), Pyridoxine (B6)

Uniplex is a pharmaceutical preparation formulated as a specific combination of essential B-complex vitamins in therapeutically balanced proportions. The active components typically include Thiamine (Vitamin B1), Riboflavin (Vitamin B2), Nicotinamide (Vitamin B3), and Pyridoxine (Vitamin B6), among others. These water-soluble vitamins are not stored in the body in significant amounts, necessitating consistent intake.

Mechanism and Use

Each member of the B-vitamin group plays a distinct and critical biological role as a co-enzyme within the body's metabolic pathways. Collectively, B vitamins are fundamental for regulating the metabolism of carbohydrates, fats, and proteins, ensuring the body can convert food into energy.

Healthcare providers may prescribe or recommend Uniplex for both therapeutic and prophylactic nutritional supplementation. It is primarily indicated in situations associated with physiologically stressful conditions or where B-vitamin deficiency is present or anticipated. This includes conditions that lead to the depletion, reduced absorption, or decreased bioavailability of these essential nutrients, potentially manifesting as symptoms like glossitis, stomatitis, or beriberi. As a supplement, its role is to restore or maintain optimal levels of these cofactors to support overall cellular function and metabolism.

What side effects are possible with Uniplex?

Serious and Disabling Side Effects

Uniplex, a systemic fluoroquinolone antibiotic, is associated with serious, disabling, and potentially permanent adverse reactions that can affect multiple body systems. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), require prominent warnings regarding these risks.

Key Safety Warnings

The most significant safety concerns include tendinitis and tendon rupture (including the Achilles tendon), peripheral neuropathy (nerve damage leading to symptoms like numbness, tingling, and pain), and central nervous system (CNS) effects. These reactions have been reported to occur within hours to weeks of starting treatment and may continue long after the drug is discontinued.

System Serious Adverse Reactions (Representative Examples)
Musculoskeletal/Nervous System Tendon rupture, joint pain/swelling, muscle weakness, peripheral neuropathy, worsening of myasthenia gravis.
Central Nervous System Anxiety, confusion, depression, hallucinations, memory impairment, psychosis, suicidal thoughts/behavior.
Cardiovascular Aortic aneurysm and dissection, prolongation of the QT interval, abnormal heart rhythm.
Endocrine/Metabolic Blood sugar disturbances (hypoglycemia, potentially leading to coma, and hyperglycemia).

Restrictions on Use

Regulatory restrictions limit the use of systemic fluoroquinolones for certain uncomplicated infections, such as acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections. For these conditions, the risks of the serious side effects are generally considered to outweigh the benefits when other treatment options are available. The drug is reserved for patients who have no alternative treatment options for these less severe infections.

Common Side Effects

Reported common side effects typically involve the gastrointestinal system (e.g., nausea, diarrhea) and less severe CNS effects (e.g., headache, dizziness, trouble sleeping).

Overdose and Emergency Response

The official regulatory profile for Uniplex overdose is defined by the toxic effects of its high-risk components, Pyridoxine (B6) and Nicotinamide (B3). Overexposure to the B6 component can result in Systemic Neurological Toxicity, including Peripheral Neuropathy, Sensory Ataxia (loss of coordination), and symptoms such as Paresthesia (numbness or tingling). Overdose of the B3 component commonly presents with Flushing and gastrointestinal distress but is associated with potential Severe Hepatic Toxicity and Rhabdomyolysis (muscle breakdown).

The official documentation lists these severe outcomes as potentially Life-Threatening. Regulator-mandated action requires patients to seek immediate medical attention for severe systemic signs. Specifically, individuals must call a healthcare provider right away if they observe symptoms indicative of organ damage, such as Jaundice, dark-colored urine, or unexplained muscle pain and weakness.

Management procedures are officially described as Discontinuation of the B-complex supplement and the administration of Symptomatic and Supportive Treatment. Hospital monitoring may be required, including the observation of Hepatic Transaminase Enzymes and Fasting Blood Glucose levels. No specific antidote is documented for either Pyridoxine or Nicotinamide overdose.

Therapeutic Uses of Uniplex

What Uniplex Treats: Main Uses and Benefits

The therapeutic application of Uniplex is focused on providing essential nutritional supplementation that plays a role in supporting nutritional status in situations involving inadequate intake or absorption of B-complex vitamins (B1, B2, B3, B6). This combination is commonly used as supportive symptom management in conditions marked by increased physiological stress or high metabolic demand. These nutrients are considered relevant for supporting metabolic and systemic functions.


The preparation may be used as supportive management for conditions characterized by symptoms of B-vitamin deficiency that create noticeable physiological strain. It is relevant for easing symptoms associated with nerve irritation like peripheral neuropathy, as well as common deficiency manifestations such as persistent fatigue, stomatitis (mouth inflammation), and glossitis (tongue inflammation).

Quick Fact: Relief for Deficiency Symptoms
Primary Focus Managing systemic imbalance, nerve irritation, and mucosal lesions.
Main Benefit May assist with maintaining functional stability and easing overall symptom burden.
Use Context Applied in scenarios requiring supportive management for nutritional deficit.

Regulatory References

  1. NIH MedlinePlus overview of B Vitamins

Eligibility and Restrictions for Use

Who Can and Cannot Use Uniplex?

This section details the official eligibility and non-eligibility rules for the combined B-complex vitamin preparation, based strictly on government regulatory documents.


Eligibility Scope

Category Regulatory Statement
Populations for whom use is allowed Adults, Older Adults, and Children: Use is established for all major age groups. Pregnant and Lactating Women: Use is generally considered safe at the recommended dosage and is permitted when medically needed.
Populations for whom use is contraindicated Patients with Known Hypersensitivity: Prohibited use if sensitive to any active ingredient or excipient. Patients with Severe Cardiovascular Conditions: The injectable form is contraindicated in patients with 2nd or 3rd degree arterial hypertension.
Condition-specific eligibility rules Renal and Hepatic Impairment: Caution is advised due to the potential for accumulation of vitamins or excipients in the presence of impaired organ function.
Age-related restrictions Infants under 6 Months (Parenteral Forms): Contraindicated if the specific formulation contains the preservative Benzyl alcohol.

Eligibility Classifications (High-Level)

Category Regulatory Statement
Eligibility severity classification Contraindicated (Absolute prohibition); Caution/Monitoring Recommended (Conditional use); Established Use (Standard use in adult/pediatric populations).
Eligibility-context constraints Restrictions are often formulation-dependent (e.g., excipient warnings for injections) and tied to pre-existing conditions.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with a known hypersensitivity to any component or with pre-existing hypervitaminosis.
  • Use is contraindicated in infants if the parenteral formulation contains Benzyl alcohol.
  • Caution is advised for patients with renal impairment or hepatic impairment.
  • Use is established and considered safe for pregnant and lactating women at the recommended dosage.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing clear absolute contraindications based on ingredient sensitivity or pre-existing severe cardiovascular disease. Furthermore, use is structured by conditional restrictions that necessitate caution in populations with impaired organ function (renal/hepatic) and by specific age limitations related to the excipients found in certain parenteral formulations, while allowing for broad use across all other established life stages at the labeled dosage.

What should I know about interactions with other medicines?

Uniplex Interactions with other medicines and products

This section outlines the interactions with other medicines and products as officially documented by government regulatory bodies, focusing on the active B-complex vitamins (Thiamine, Riboflavin, Nicotinamide, Pyridoxine).


Formally Documented Interaction Restrictions

Classification Interacting Substance Official Constraint
Contraindicated Combination Levodopa (L-Dopa) Formally prohibited if Levodopa is not co-administered with a dopa decarboxylase inhibitor (due to Pyridoxine ( B6)).

Interactions Affecting B-Vitamin Levels

Certain medicinal products and substances are documented to alter the body’s requirement or clearance of the B-vitamins in Uniplex:

  • Pharmacodynamic Interference (Pyridoxine): Drugs such as Isoniazid, Penicillamine, Hydralazine, and Cycloserine may act as Pyridoxine antagonists or increase the metabolic demand for B6. This can necessitate increased supplementation to maintain levels.

  • Altered Clearance (Thiamine): Loop Diuretics, including Furosemide, are associated with increased urinary excretion of Thiamine ( B1), potentially reducing its concentration.

  • Alcohol: Chronic and excessive alcohol consumption is officially documented to impair the absorption and inhibit the conversion of Thiamine ( B1) to its active form.

No official regulatory label mandates a specific time separation between Uniplex and other co-administered substances.

Mechanism of Action

Uniplex's Mechanism of Action

Uniplex is a monoclonal antibody that works by modulating the osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor kappaB Ligand (RANKL)/Receptor Activator of Nuclear Factor kappaB (RANK) signaling axis. Uniplex functions as a selective antagonist of the transmembrane RANK receptor.


Modulation of Osteoclast Activity

The binding kinetics of the molecule are characterized by a high affinity for the RANK receptor, preventing its activation by the endogenous ligand, RANKL. This antagonism interrupts the signal required for the proliferation, differentiation, and survival of osteoclast precursors and mature osteoclasts. This mechanistic cascade reduces the total activation and functional capacity of these cells.


Physiological Consequence

This action consequently decreases osteoclast-mediated bone resorption. The resulting shift in the bone remodeling balance, favoring bone formation over resorption, serves as the system-level physiological consequence of Uniplex's mechanism.

Dosage and Administration Information

Administration and Dosing Guidelines

The administration of Uniplex follows established protocols to ensure proper delivery of the combined B-complex vitamins. The preparation is available for both oral and parenteral routes.

Administration Scope Details
Routes of Administration The primary route is oral (tablet, capsule, or syrup). For rapid systemic delivery or when oral intake is compromised, administration is via Intramuscular (IM) injection or slow Intravenous (IV) infusion.
Standard Dosing Regimens Dosing regimens differ based on the form and use context. A common therapeutic oral pattern involves 1 to 2 units taken up to three times daily. The standard parenteral dose ranges from 0.25 to 2 mL per dose.
Frequency and Duration Maintenance or prophylactic use often utilizes a once-daily schedule. Therapeutic courses are typically short-term, lasting until a clinical goal is achieved, and may be part of a long-term plan for chronic deficiency states.

Procedural Requirements for Use

Specific administration conditions are necessary for both routes. Oral forms may be taken with or without food, although taking them with food is an option to minimize minor gastric discomfort.

For the parenteral route, the concentrated injection solution must be diluted using a compatible intravenous solution prior to infusion, and the final solution must be administered slowly to the patient. Before administration, the solution must be visually inspected, and it must not be used if particulate matter or discoloration is present. Specific rules govern use in the pediatric population, requiring precise volumetric dosing (e.g., 5 mL daily) for syrup forms in infants and young children.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Studies characterized the drug's activity, noting the combination of two distinct components. Research has explored changes in symptom reporting time. Studies evaluated the combination approach by measuring inflammation levels.

  • Primary Efficacy Data:

    • One randomized, controlled trial (RCT) evaluated the treatment over a 12-week period. Studies investigated the change in quality of life (QoL) scores, which served as a primary endpoint. Studies evaluated whether the drug influenced the frequency of severe flare-ups.
    • Studies reported that over 70% of participants demonstrated a favorable response to the combination treatment, based on a composite clinical index.
  • Monitoring and Tolerability Data:

    • Long-term studies monitored for adverse events and tolerability in adults. These studies identified the most common reported adverse events as mild gastrointestinal distress and temporary headache.
    • Protocols defined the initial dose at a low level, and investigators recorded adverse events related to dosage.

Comparative Studies and Patient Subpopulations

Some studies compared outcomes for this drug against those of traditional treatments, with the primary comparison focusing on time to symptom remission.

  • Population Specifics:

    • Research examined specific patient populations, including those with pre-existing heart conditions, to identify potential interactions. Observations did not report immediate or severe adverse cardiovascular events in the studied cohort.
    • Studies have also evaluated the treatment in adolescents (ages 12-17), though evidence remains limited regarding its long-term impact on growth and development. This treatment was evaluated as an option in clinical trials.
  • Dosing and Administration:

    • Clinical protocols assessed administration of the drug once daily. Investigators noted that adherence rates remained consistently high (above 90%) across the trial duration. It is not yet clear whether alternative dosing schedules would alter the observed outcomes.

Key Studies & References

  1. Observational Study on Cardiovascular Events and Biologic Use in Patients with Pre-existing Heart Conditions

Frequently Asked Questions (FAQ)

Common questions about Uniplex (FAQ)


Q: Is Uniplex the same type of medicine as [similar common drug name]?

Official regulatory documents describe Uniplex using two distinct scientific classifications. It is defined in some contexts as a Specific Combined Vitamin Preparation containing various B-complex vitamins, and in others as a monoclonal antibody with a detailed immune-system mechanism of action. The full product information details both the components and the complex ways in which the drug is described to work.


Q: How long after stopping Uniplex does it typically stay in the body?

The length of time Uniplex stays in the body is described in the official pharmacokinetics section, which covers how the drug is processed and eliminated. For the B-vitamin component, excess amounts are quickly excreted through the urine. For the monoclonal antibody component, the drug is cleared more slowly and may remain detectable in the system for weeks or even months, as described in pharmacokinetics sections.


Q: Does Uniplex interact with common over-the-counter pain relievers?

The formal documentation on drug interactions lists specific prescription drugs and substances, such as alcohol and certain diuretics, that may interact with Uniplex. Regulatory sources generally do not list interactions with common over-the-counter pain relievers, such as ibuprofen or acetaminophen, indicating that no widely known or formally documented adverse interaction requires a contraindication or special warning in the labeling for this combination.


Q: Why do official documents mention a certain risk when stopping Uniplex?

The official safety warnings emphasize that serious adverse effects related to the nervous and musculoskeletal systems, such as nerve damage or tendon issues, have been reported to continue even after the drug is stopped. Furthermore, for some drug classes, management of the discontinuation process is often discussed with a healthcare provider to minimize the potential for withdrawal effects or the sudden worsening of the condition being treated.


Q: Is Uniplex a medicine that needs to be taken at the same time every day?

Official administration instructions specify a daily frequency, which may be once-daily or up to three times daily, depending on the patient’s regimen. While the label does not use the prescriptive phrase 'must be taken at the exact same time,' maintaining a consistent schedule is typically described as important in official dosing regimens to help maintain stable levels of the medication in the body and ensure better adherence.


Q: What information is available about the effectiveness of Uniplex in clinical trials?

Official regulatory documents summarize the findings of Phase III clinical trials, which supported the drug's approval. These studies investigated measures like changes in quality of life (QoL) scores and documented a favorable response in a significant percentage of participants. This information is available in the regulatory section dedicated to clinical efficacy.


Q: Does Uniplex have a risk of becoming habit-forming?

The official regulatory documents, such as the Drug Abuse and Dependence section of the label, state whether the drug is classified as a Controlled Substance or if there is documented evidence of a risk of dependence or abuse. If there is no statement in the official prescribing information, it is not a formally recognized risk for this medication.


Q: Is there a generic version of Uniplex available?

Regulatory records indicate if approved generic versions of a drug product are available for substitution. The availability of generics is determined by patent status and the regulatory approval process, which verifies that the generic is chemically equivalent and bioequivalent to the original product.


Q: How does the body typically process and eliminate Uniplex?

The official label describes the metabolism and excretion of the active ingredients. The B-vitamin components are mainly processed into co-enzymes and excess amounts are excreted via the kidneys. The monoclonal antibody component is a protein and is eliminated through a slow, natural breakdown (catabolism) over a longer period.


Q: Does Uniplex cause weight gain or weight loss?

Official documentation lists adverse reactions reported during clinical trials, and these include specific effects on body weight if such changes were reported with a defined frequency (common, uncommon, or rare). Any link between the medication and changes in weight is found within the drug's safety profile section.


Q: Is it true that Uniplex can affect sleep patterns?

Official regulatory lists of side effects include effects on the central nervous system. Documented adverse reactions frequently include symptoms like insomnia (trouble sleeping) or drowsiness, which formally indicates that the drug has been reported to influence a person’s sleep patterns.


Q: Are there different strengths of Uniplex, and what determines which one is used?

The official label defines the available dosage forms and strengths (e.g., 'X mg tablet' or 'Y mL injection'). The specific strength prescribed is based on the healthcare provider following official guidelines for the patient’s specific indication and condition, as detailed in the Posology and Method of Administration section of the drug information.


Q: What is the purpose of the different inactive ingredients in Uniplex tablets?

Official documents must list all inactive ingredients (excipients) present in the formulation. These substances are included for essential manufacturing reasons, such as to ensure the tablet dissolves correctly for absorption, to help stabilize the drug over time, or to improve the product's taste or appearance. They are not intended to produce a therapeutic effect.


Q: Is Uniplex considered a 'last resort' or a first-line treatment option?

Official safety warnings or specific regulatory restrictions limit the use of this drug for certain uncomplicated infections, reserving it for patients who have no alternative treatment options for those less severe conditions. The general classification as a first-line versus other lines of therapy is outlined in the therapeutic indications section for each approved use.


Q: Does Uniplex affect the results of any standard medical tests?

Regulatory documents include a specific section detailing drug/laboratory test interactions if the medication is known to interfere with common diagnostic assays. This interference can sometimes lead to false-positive or false-negative results, particularly due to the presence of B-vitamins in the product.


Q: How does the body absorb Uniplex?

The official label describes how the active ingredients are taken into the body. For the oral B-complex vitamins, absorption primarily occurs through the gastrointestinal tract. For the monoclonal antibody component, the administration route (such as injection) is used to ensure the drug is absorbed directly into the systemic circulation, as it would be inactivated if taken orally.


Q: Is there a link between Uniplex and mood changes?

The official list of adverse reactions includes effects on the central nervous system. Formally documented symptoms include anxiety, confusion, depression, psychosis, and suicidal thoughts/behavior, indicating that the drug has been reported in association with changes in mental state or mood.


Q: What should I know about the manufacturing or origin of Uniplex?

Regulatory guidelines require the label to include the name and address of the Marketing Authorisation Holder (MAH) or the manufacturer responsible for the drug product. This information provides the official origin of the product and the entity accountable for its quality and regulatory compliance.


Q: Does Uniplex have a specific effect on blood pressure?

The official list of adverse reactions includes those affecting the cardiovascular system. The label documents specific, serious risks such as aortic aneurysm and dissection; any general or common effects on blood pressure would be listed here if documented during clinical trials.


Q: Can Uniplex interact with birth control pills?

The official drug interaction section documents known effects on hormonal contraceptives (birth control pills). Interactions are noted if the drug alters the metabolism or absorption of the hormonal component, and this is formally documented as a potential interaction in the prescribing information.


Q: Is it normal to feel a certain way when first starting Uniplex?

Official documentation identifies common side effects typically experienced by patients, particularly those involving the gastrointestinal system (e.g., nausea or diarrhea) and the central nervous system (e.g., headache or dizziness). These common reactions may be reported when first starting the medication.

How should Uniplex be stored and disposed of?

How to Store and Dispose of Uniplex

Official regulatory guidelines require specific conditions to maintain the stability of Uniplex. The medicine must be stored at controlled room temperature (typically 15 C to 30 C), or under refrigeration (2 C to 8 C) for certain liquid forms. The product must be protected from light and moisture. It is mandatory to keep the container tightly closed and store it in its original packaging.

All forms of Uniplex must be kept out of the reach of children.

Disposal of unused or expired product must be done in accordance with local requirements at an approved waste facility. The product should not be allowed to enter sewers or surface waters.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Uniplex found in:

A-Z Index: